Status:
COMPLETED
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
Lead Sponsor:
Seqirus
Conditions:
Influenza Caused by the Novel Influenza A (H1N1) Virus
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.
Eligibility Criteria
Inclusion
- Male or female aged \>= 18 to \< 65 years at the time of providing informed consent.
Exclusion
- Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the Study Vaccine.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00938639
Start Date
July 1 2009
End Date
March 1 2010
Last Update
June 28 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Study Site
Adelaide, South Australia, Australia, 5000